Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186898 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
A Phase 3 study of Unresectable Hepatocellular Carcinoma and Recurrent Hepatocellular Carcinoma, sponsored by NRG Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 186
- Enrollment target
- 20
- Study locations
NCT03186898 is a Phase 3 study of Unresectable Hepatocellular Carcinoma and Recurrent Hepatocellular Carcinoma that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 186 participants, above the 71-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (162% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT03186898, a Phase 3 study of Unresectable Hepatocellular Carcinoma and Recurrent Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by NRG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 186 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging
- OTHER Laboratory Biomarker Analysis
Study Locations (20)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- New York Proton Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
Georgia
- Emory Proton Therapy Center - Atlanta
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
Michigan
- Corewell Health Dearborn Hospital - Dearborn
- Corewell Health William Beaumont University Hospital - Royal Oak
- Corewell Health Beaumont Troy Hospital - Troy
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Maryland
- Maryland Proton Treatment Center - Baltimore
- University of Maryland/Greenebaum Cancer Center - Baltimore
Illinois
- Northwestern Medicine Cancer Center Warrenville - Warrenville
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03186898
The ClinicalTrials.gov registry entry for NCT03186898 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 71-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (162% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03186898 reports 20 study locations spanning 8 distinct geographic areas - top geographies include New York, Georgia, Michigan.
Frequently Asked Questions
What is clinical trial NCT03186898 about?
NCT03186898 is a clinical study titled "Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer". This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton pa...
What is the current status of trial NCT03186898?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 2018-01-26. Estimated completion is 2027-06-30.
What conditions does trial NCT03186898 study?
This clinical trial studies the following conditions: Unresectable Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7.
What interventions are being tested in trial NCT03186898?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT03186898?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03186898 being conducted?
This trial has 20 study locations across Georgia, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RECRUITING · Phase 1
-
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
RECRUITING · Phase 1
-
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
RECRUITING
-
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Unresectable Hepatocellular Carcinoma
All registered trials for this condition
Recurrent Hepatocellular Carcinoma
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.